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Oxidative stress plays an important role in cystic ﬁbrosis (CF). However, there is a lack of validated biomarkers of oxidative damage that
correlate with the antioxidant needs of patients with CF.
Objective: To investigate oxidative stress in stable pediatric CF patients and evaluate if vitamin supplementation may be tailored to individual
needs and oxidative status.
Results: Lipid-adducts 4-hydroxynonenal (HNE-L) and malonaldehyde (MDA-L) (chromolipids) were elevated in the majority of patients despite
normal plasma vitamin E, A and C. HNE-L and MDA-L increased with age, while plasma vitamins decreased. The most relevant correlation was
identiﬁed between vitamin C and chromolipids. Patients with pancreatic insufﬁciency (PI) showed signiﬁcantly higher plasma chromolipids
despite no differences in plasma vitamins.
Conclusions: The majority of patients showed elevated plasma chromolipids that increased with age. Antioxidant vitamin reference ranges provide
incomplete information on the redox status. CF patients with PI showed excessive oxidative stress damage.
© 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Lipid oxidation; Nutrition; Antioxidant vitamins; Pancreatic insufﬁciency1. Introduction
Cystic fibrosis (CF) is characterized by elevated oxidative stress
and impaired antioxidant/oxidant balance [1]. Chronic infection
and inflammation increase the free radical production. This could
modulate the CFTR expression and function having a role in lung
disease progression [2]. At the same time, antioxidant defenses are⁎ Corresponding author at: Dept. Clinical Nutrition, University of Turin - OIRM-
Sant'Anna Hospital, Piazza Polonia 94, 10126 Turin, Italy. Tel.: +39 011 3131568;
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doi:10.1016/j.jcf.2012.06.002dramatically reduced compared to those of healthy subjects [1–3]
even early in life [4].
Respiratory exacerbations lead to impairment of antioxidant
defenses that are restored after treatment [5]. Increased number of
exacerbations has also been correlated to lower plasma vitamins
E and A [6]. Furthermore, markers of free radical damage have
been demonstrated in plasma of CF patients despite the presence
of normal concentrations of circulating antioxidants suggesting
inadequate antioxidant defenses to cope with elevated oxidative
stress with consequent progressive decline in pulmonary function
[4,7].
An important feature in CF patients is the exocrine pancreatic
insufficiency (PI), which causesmaldigestion andmalabsorption ofby Elsevier B.V. All rights reserved.
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replacement therapy (PERT) does not completely restore the
absorption of these vitamins. Moreover, it has been demonstrated
that vitamin deficiency can be independent of pancreatic function
and PERT [8]. Therefore, CF patients with PI need to receive
daily vitamin supplements. The monitoring of plasma levels
and supplementation of these vitamins is part of routine CF
care [9,10].
Normal ranges of plasma antioxidants correspond to those
regarded as adequate for the non-CF population i.e. healthy
subjects. The optimal requirements for CF patients, based on
antioxidant needs, may be higher than these. Discussion on
vitamin status has now shifted to the identification of optimal
levels that provide better health outcomes than suboptimal
ones.
Quantification of oxidative stress can be assessed by the
detection of lipid peroxidation end-products deriving from the
degradation of polyunsaturated fatty acids, which are suscep-
tible to oxidative attack by free radicals. Several markers for
lipid peroxidation both in vitro and in vivo are available and
different detection methods have been described [11]. Among
these isoprostanes and aldehydes, such as MDA and HNE, are
now the most studied products of lipid peroxidation involved in
different respiratory pathologies [12,13]. In particular, significant-
ly elevated F2α-isoprostane has been found in breath condensate
and plasma of CF patients [2,14]. Significantly elevated MDA in
terms of thiobarbituric acid reactive substances (TBARS):
cholesterol ratio, have been described to increase with age in
CF patients [3]. Compared to isoprostanes, the longer half-
life of aldehydes makes them good candidates for propaga-
tion and amplification of effects elicited by free radicals.
Among aldehydes, HNE is highly reactive with thiol- and
amino-residues of proteins, peptides, lipids and nucleic acids
[15].
High MDA concentrations have been found to be negative-
ly correlated with forced expiratory volume in 1 s (FEV1) in
different airway diseases [2,3,16,17]. Significant reduction
and/or normalization of MDA plasma concentrations has been
reported after beta-carotene or multivitamin supplementation
in CF patients [18,19]. However, consideration should be
given to the risk of toxicity and side-effects induced by the
high dose liposoluble vitamin supplementation. Although
there is growing evidence of the potential role of oxidative
reactions in the pathogenesis of CF, we still lack validated
biomarkers of oxidative damage, which might serve to identify
the effective amounts of antioxidants actually needed by CF
patients.
The present study was carried out to address this issue. The
fluorometric assay of aldehyde-lipid adducts in plasma has been
assessed exploiting the properties of MDA and HNE to be highly
reactive forming stable adducts with functional groups of cell
macromolecules [20]. The aimwas to identify the oxidative status
in a group of stable CF patients in relation to their antioxidant
and clinical status, in the presence or absence of pancreatic
insufficiency. These results may provide suitable “individual”
reference ranges for a proper vitamin supplementation in CF
patients.2. Materials and methods
2.1. Patients' recruitment
We enrolled 70 subjects, 1–18 years old, progressively
attending the Pediatric Cystic Fibrosis Centre (ReginaMargherita
Hospital, Turin) from January 2007 to April 2008. All patients
were in stable clinical condition and were evaluated during the
routine control visit. Our study included:
Clinical data. Genotype, pancreatic insufficiency (fecal elasta-
seb200 μg/g), number of respiratory exacerbations during the
last year.
Anthropometric measurements. Body weight (kg, percentile,
z-score), height/length (cm, percentile, z-score), body mass
index (kg/m2, percentile, z-score) calculated by Epi-Data
Nut Stat (Epi Info 2000; developed by the CDC—Center for
Disease Control and Prevention—in Atlanta, Georgia, USA).
Respiratory function test (RFT) was performed with a Bio
Medine spirometer.
We calculated the mean value of the last year (for patients
older than 6 years that were able to perform RFT) for FEV1
expressed as percentage of the predicted value for age and
sex.
Vitamin supplementation. Dosages of vitamins E and A and
multivitamins were recorded.
Nutritional evaluation. A three-day-food-record was analyzed
to calculate the intake of energy, nutrients and antioxidants
(software based analysis — Food Meter, Medimatica s.r.l.,
Martinsicuro, Teramo, Italy, 1990, modified by Turin
University according to the Nutrition Tables of Italian
National Institute of Nutrition). Patients or parents were
required to record prospectively the food consumed through
3 days. Food quantities were described by using standard
household measures (e.g. cups, tablespoons) or weighed if the
latter were not available. The cooking method was also
described. In the end, during the visit session, a dietitian went
through the record with patients/parents to clarify details.
Hematic parameters of antioxidant status: selenium, ascor-
bic acid, retinol and α-tocopherol in plasma samples, selenium
dependent glutathione-peroxidase (GSH-PxSe), reduced glu-
tathione (GSH) in red blood cells were considered biochemical
indexes of antioxidant status.
Selenium (P-Se) was detected by SpectrAA 20 Graphite
Furnace Atomic Absorption Spectroscope Varian (Varian
Techtron Pty. Ltd., Australia); ascorbic acid was detected in
plasma samples by HPLC (high pressure liquid chromatography)
according to Harapanalli [21]. Retinol and α-tocopherol were
simultaneously evaluated by HPLC using a kit of Chromsys-
tems Instruments and Chemical GmbH (Martinsried/Munich,
Germany). Selenium-dependent-glutathione peroxidase ac-
tivity in red blood cells (RBC) was evaluated by spectropho-
tometrically [22]. Total and reduced glutathione was analyzed by
HPLC after derivatization of hemolyzed samples with ammonium
7-fluorobenzo-2-oxa-1,3-diazole-4-sulphonate (SBD-F) (fluores-
cence detector Varian 9070, 385 nm excitation/515 nm emission).
Table 1
Characteristics of study population.
Pts. no. (%) Median (range)
Age (yrs) 70 (100%) 7.8 (1.1–19)
Sex (M/F) 32/38
Genotype
Homozygous ΔF508 16 (22.9)
Heterozygous ΔF508 33 (47.1)
Other/other 21 (30)
Pancreatic insufficiency 36/70
BMI z-score 70 (100) −0.03 (−4.2−2.7)
FEV1 (% predicted) 45 (64.3) 90 (33.8–118)
Supplementation
Vitamin E (mg) 64 (91.4) 100.8 (100–300)
Vitamin C (mg) 45 (64.3) 1249.5 (624–2499)
Vitamin A (μg) 50 (71.4) 25 (10.4–60)
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(mg/l), ascorbic acid (mg/l), retinol (μg/l) and selenium (μg/l),
reduced RBC-glutathione (GSH-μmol/gHb), selenium depen-
dent glutathione peroxidase (GSH-PxSe-U/gHb).
The study population was classified in clusters of optimal,
suboptimal and deficient plasma vitamin E and C as described
by Biesalski [23]. For vitamin A we utilized the 25th and 90th
percentile of retinol concentrations as cut-off values similar to
those proposed by Biesalski that deals with beta carotene.
2.2. Oxidative stress markers
The presence of oxidative damage was assessed in plasma
by determining the fluorescent adducts formed between lipid
peroxidation-derived aldehydes and plasma lipids, also termed
chromolipids. In particular, samples were extracted in chloroform/
methanol (2/1 v/v). Lipid soluble layers were collected, dried
under nitrogen and resuspended in 1 ml chloroform plus 0.1 ml
methanol for fluorometric measurements. HNE-lipid adducts
(355 nm excitation/460 nm emission) and MDA-lipid adducts
(390 nm excitation/460 nm emission) were evaluated using a
Kontron SFM 25 spectrofluorometer (Kontron AG, Zurich,
Switzerland). Data were expressed as arbitrary fluorescence units
(A.F.U.)/ml plasma and, as required, arbitrary fluorescence units/
mg plasma cholesterol. Plasma cholesterol was analyzed by an
enzymatic colorimetric test (Olympus analyzer).
Oxidative status was also estimated in RBC as a ratio of
reduced glutathione and its oxidized form (GSSG). GSSG was
calculated by HPLC as the difference between total and
reduced glutathione.
2.3. Statistical analysis
Data are reported as median and range for continuous variables
and number and percentage for categorical ones.
Differences between groups were evaluated with the Mann–
Whitney U test or the Kruskal–Wallis test, while correlation
between continuous variables was checked with the Spearman
correlation coefficient (ρs). All tests are two-sided and significant
for p values less than 0.05.
Data were analyzed with SPSS 17 (SPPS Inc., Chicago, IL).
3. Results
General and clinical characteristics of the study population
are reported in Table 1.
3.1. Redox status in CF pediatric patients
Referring to the local reference range, the majority of patients
had normal concentrations of vitamins E, A, C and selenium
(92.8%, 97.1%, 98.6% and 86.6%, respectively). Red blood cell
concentrations of reduced glutathione and glutathione peroxidase
(97% and 97% respectively) were also recorded and found to be
normal. Interestingly, the GSH/GSSG ratio was low for 89.7% of
patients.Chromolipids HNE-L and MDA-L, either as plasma levels or
referred to mg of plasma cholesterol, were significantly higher
than those of healthy people (local reference range — l.r.r.).
Specifically, only 4.8% and 1.6% of patients showed normal
concentrations of HNE-L and MDA-L respectively.3.2. Evaluation of energy and nutrient intakes
Analysis of three day food record revealed adequate energy
and macronutrient intakes per kilogram of body weight and in
percentage of total energy referring to Italian recommended
intakes (LARN — Livelli di Assunzione Raccomandata di
energia e Nutrienti) [24], though not as high as expected for CF
patients (energy 81 kcal/kg, lipids 33.7%, protein 16% and
carbohydrates 52.3%). Vitamin A and E intakes were aligned to
the above mentioned recommendations while vitamin C intake
was slightly superior (78.4 vs. 40–60 mg/day).3.3. Plasma antioxidant vitamins: relationship to clinical data
and oxidative stress parameters
Classifying the study population on the basis of the optimal,
suboptimal and deficient levels suggested by Biesalski [23], we
observed a quite different picture from the one obtained relying
on the local reference range of normality for plasma vitamins.
A large group of patients (67.1%, 40.6% and 65.7%) showed
sub-optimal plasma levels of vitamins E, C and A respectively,
running the risk of oxidative burden (Table 2). Since the sub-
optimal levels are within the normal reference range, patients
do not usually increase their supplementation doses. However,
21.5% and 22.8% of patients had deficient levels of vitamins E
and A despite oral vitamin supplementation.
Age was the most relevant characteristic across the different
clusters of patients: patients with optimal values are significantly
younger than those with lower/deficit vitamin levels (pb0.05 for
vitamins E and C) (Table 2).
Plasma oxidative stress markers HNE-L and MDA-L as well
as the ratio with plasma cholesterol showed an increasing trend
with lowering antioxidant vitamin concentrations. Interestingly,
the difference is statistically significant between patients with
Table 2
Clinical characteristics and oxidative stress markers in patient groups with different antioxidant vitamin levels a.
Vitamin E–C–A Vitamin E (mg/l) Vitamin C (mg/l) Vitamin A (μg/l)
Optimal N12.9 Suboptimal
6.9–12.9
Deﬁcit b6.9 Optimal N8.8 Suboptimal
1.9–8.8
Optimal N676 Suboptimal
373–676
Deﬁcit b373
Pts. Nr (%) 8 (11.4) 47 (67.1) 15 (21.5) 41 (59.4) 28 (40.6) 8 (11.4) 46 (65.7) 16 (22.8)
Age (yrs) 4.6 (1.9–7.9) ⁎ 8.8 (1.1–19) ⁎ 7.0 (1.1–18) ⁎ 7.4 (1.1–14.9) ⁎ 12.6 (1.1–19) ⁎ 7.3 (1.1–19) 7.6 (1.1–18) 8 (5.2–18)
Exacerbations/year 1.1 (0–4) 1.3 (0–12) 1.4 (0–8) 1.2 (0–7) 1.1 (0–12) 0 (0–2) 0 (0–7) 1.5 (0–12)
BMI Z-score 0.2 (−1.5–1) 0.01
(−2.7–2.7)
−0.6
(−4.2–1.7)
0.2
(−2.8–1.9) ⁎
−0.5
(−4.2–2.7) ⁎
0.2
(−2.6–1.9)
0.01
(−2.8–2.7)
−0.7
(−4.2–1.7)
FEV1(% predicted) b 92.6 (91–95) 93.5 (34–118) 82.4 (44–100) 90.6 (40.3–118) 85.1 (33.8–112) 92.0 (85–118) 93.5 (40–112) 82.4 (34–111)
HNE-L/cholesterol
(UF/mg chol)
1.6 (1.0–2.3) 1.5 (0.5–3.2) 1.9 (1.1–2.9) 1.4 (0.5–3.2) ⁎ 1.9 (0.8–2.9) ⁎ 1.2 (0.5–1.8) 1.5 (0.9–3.2) 1.9 (0.8–2.9)
MDA-L/cholesterol
(UF/mg chol)
0.8 (0.5–1.5) 0.8 (0.3–3.8) 0.9 (0.5–2.6) 0.8 (0.3–3.8) ⁎ 0.9 (0.5–3.3) ⁎ 0.8 (2.3–1.1) 0.8 (0.5–3.8) 0.9 (0.5–2.7)
ErGSH/GSSG 3.3 (1.6–6.5) 4.1 (1.3–13.6) 3.2 (2.6–9.7) 3.3 (1.3–13.6) 4.4 (2.3–11.1) 5.5 (1.9–9.7) 3.8 (1.2–13.6) 4.4 (2.1–11.4)
All values expressed as median (range).
a Classiﬁcation suggested by Biesalski [23].
b Mean value of determinations in last year-data available in 45/70pts.
⁎ pb0.05.
Fig. 1. Effect of age on plasma chromolipids. 4‐hydroxynonenal andmalonaldehyde
are expressed as HNE‐L/mg cholesterol andMDA‐L/mg cholesterol respectively. ρs:
Spearman rank correlation coefficient.
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chromolipids.
There were no differences among groups for the clinical
data.
BMI z-score was significantly lower in patients with suboptimal
vitamin C concentrations (pb0.05) compared to thosewith optimal
ones (Table 2).
3.4. Correlation of age with plasma antioxidant vitamins and
oxidative stress markers in CF patients
Plasma antioxidants were inversely correlated with age that
exerts an independent significant effect in reducing vitamin E (ρs=
−0.25, p=0.034) and vitamin C (ρs=−0.27, p=0.025). Although
plasma vitamin A also claimed an inverse correlation with age, it
was weaker and statistically insignificant(ρs=−0.06; p=0.628).
Plasma chromolipids increased significantly with age (MDA-L/
cholesterol ρs=0.36, p=0.003; HNE-L/cholesterolρs=0.33,
p=0.004) (Fig. 1). Aging accounted for 10% (MDA-L) and
12% (HNE-L) of the increase in plasma chromolipids.
3.5. Do antioxidant vitamin plasma levels correlate with
oxidative status?
Our data evidenced an inverse relation between plasma
concentrations of both chromolipids and those of antioxidant
vitamins (Fig. 2). In particular, vitamin C showed a significant
inverse correlation with plasma chromolipids (ρs=−0.30,
p=0.018 for MDA-L/cholesterol; ρs=−0.36, p=0.004 for
HNE-L/cholesterol).
3.6. Effect of pancreatic insufficiency on oxidative stress
markers
Patients with or without PI showed similar plasma vitamins
and GSH/GSSG ratio in their plasma. Again, plasma chromo-
lipids were significantly higher in patients with PI compared tonon-PI ones despite the vitamin supplementation compliant
with international recommendations. A clear graphical descrip-
tion of the differences between the two groups is shown in
Fig. 3.4. Discussion
Our data revealed that the majority of our CF patients showed
elevated oxidative stress markers even in stable clinical conditions
Fig. 2. Correlation between chromolipids and antioxidant vitamin plasma levels. Upper panel: correlation between 4‐hydroxynonenal (HNE‐L/cholesterol) and
plasma levels of vitamin E (A), vitamin A (B), vitamin C (C). Lower pane: correlation between malonaldehyde (MDA‐L/cholesterol) and plasma levels of vitamin E
(D), vitamin A (E), vitamin C (F). ρs, Spearman rank correlation coefficient.
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a progressive increase of plasma oxidative stress markers in
contrast with plasma antioxidant vitamins, whose availabilityFig. 3. Antioxidant vitamins and oxidative stress markers in presence and absence of
(left panel) and MDA‐L/cholesterol (right panel).decreased steadily. A similar inverse correlation was evidenced
between plasma vitamins and oxidative stress markers with
interesting and consistent results on vitamin C. Patients withPI. Chromolipids in patients with PI (1) and without PI (0): HNE‐L/cholesterol
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oxidative stress markers without significant differences in plasma
vitamins. These data suggest the necessity of a careful definition
of vitamin needs in CF patients preferably on an individual basis
considering oxidative status.
The poor antioxidant status in CF patients versus healthy
subjects has been widely demonstrated [1–3]. Plasma liposoluble
vitamins are usually determined once a year and deficient patients
are supplemented, compliant with recommendations, in order to
comply with the normality range [25,26]. Our data evidenced
adequate plasma levels of exogenous and endogenous antioxi-
dants and dietetic intakes of antioxidant vitamins in almost all
patients. Huang et al. have also documented that, with typical
supplementation, very few children had low serum vitamin E
status suggesting the necessity of dose and response studies in CF
patients [7]. Vitamin status is now considered more broadly, in
relation to specific health outcomes. When defining the adequacy
of vitamin levels as the ones within the normality range, we found
some inconsistency: 40.6% of patients with suboptimal vitamin C
were not detected by the reference range; with regard to the local
reference range we detected 7.2% of patients with deficient
vitamin E versus 21.5% indicated by the “new” classification
[23]. All of these patients showed significantly higher plasma
chromolipids than those with optimal levels (Table 2). The lower
level of our local reference range for α-tocopherol corresponds to
the 5th percentile of NHANES III [25], the same utilized by Huang
as the lower cut-off value for vitamin E [7]. Consistent with other
studies patients with optimal vitamin E status were significantly
younger and showed lower MDA-L/cholesterol [3]. We can
assume that higher levels of Vitamin E (12.9–18.9 mg/l)
provide better protection against lipid peroxidation. None of
our patients had deficient vitamin C taking no or low-dose
vitamin supplementation as multivitamins (Table 2). Vitamin
C levels decreased with age andMDA-L/cholesterol and HNE-L/
cholesterol increased with reducing plasma vitamins as docu-
mented by previous studies [2,3,26]. Reduced BMI z-score in
patients with suboptimal versus optimal vitamin C may be, at
least in part, attributed to the higher oxidative stress (Table 2).
Other studies have demonstrated the role of ascorbic acid as a
potent antioxidant [27]. It has been suggested to play a key role in
controlling CFTR activity modifying its redox state [28]. There
are no recommendations for vitamin C supplementation in CF
patients except for subjects with an unbalanced diet [9] or general
indication of a standard age-appropriate dose of multivitamins
[10] and our data confirmed the importance of vitamin C
monitoring and supplementation.
There were no significant differences in age, BMI z-score,
number of exacerbations/year and FEV1 between groups of
patients with optimal versus suboptimal or deficient vitamin
A (Table 2).
We have not observed a significant reduction of vitamin A
with age (ρs=−0.06, p=0.628) in contrast to Maqbool et al.
[29]. Mean serum retinol in that study was much higher than in
ours (800 μg/l) and 58% of patients had serum retinol above the
NHANES reference range.
Our data failed to confirm a correlation between chromolipids
and plasma retinol in our CF patients (Fig. 2) as identified in otherstudies. Wood documented an inverse correlation between and 8-
iso-PGF2α and β-carotene [2].
8-iso-PGF2α has been considered a good method to measure
lipid peroxidation. During this process a further chain cleavage
yields several aldehydes, among them MDA and HNE. These
aldehydes are highly reactive, thus the detection of their adducts
to macromolecules, i.e. chromolipids, can provide more reliable
data than other analytical methods on the extent of oxidative
damage.
Consistent with other studies [3,5] our data showed a
strong positive correlation of chromolipids with age (Fig. 1).
An overconsumption of antioxidants was also documented as a
consequence of increased oxidative stress with age. We showed
that higher vitamins E and C provided a reduction in plasma
chromolipids (Fig. 2). It has been demonstrated that high doses of
fat soluble vitamins carry the risk of toxicity, whereas the
supplementation of vitamin C does not show any important
side effects except with very high dosages [30].
Patients with pancreatic insufficiency showed higher plasma
chromolipids (Fig. 3). Interestingly, the effect persisted even
when controlled for plasma vitamins A, E and C. It may not be
fully explained by the lipid malabsorption because it was well
controlled by PERT and vitamin C is not involved. In fact we
could not evidence any difference in fat soluble vitamins in
patients with or without pancreatic insufficiency. We think it
could be ascribed to the higher rate of infections (0.64 vs 1.97,
p=0.010) and to the genotype (82% ΔF508) of the PI patients.
Our data suggest that supplementation strategies might consider
these oxidative stress markers in addition to the plasma antioxidant
vitamins, at least in patients with pancreatic insufficiency.
However, this statement needs to be validated through further
research, with a focus on identifying reliable markers of oxidative
status to be correlated to the clinical state.
The principal limitation of our study is the limited number of
oxidative stress markers considered. In particular, exhaled breath
or sputum analyses were not evaluated. Blood antioxidants reflect
the overall capacity of the organism to afford oxidative stress
burden.Moreover, the airways experienced higher oxidative stress
because of the defective glutathione transport through the epithelial
cells for the CFTR mutation. We assume that antioxidant vitamins
exert different roles on plasma and airways. However, completing
data of the present study with further studies focused on
antioxidants and oxidative damage markers specific for the
airways may be useful to better understand the complex redox
imbalance in CF.
5. Conclusions
Oxidative stress characterizes CF patients from the pediatric
age and it progressively increases over the years. Reducing its
harmful impact is an important clinical goal. This may be
achieved with the optimization of antioxidant vitamin status.
Reference ranges for healthy people provide incomplete
information. The good management of redox balance in CF
patients requires reference ranges elaborated on the basis of data
from adequate control population. Aldehyde-lipid adducts may
be used to characterize oxidative status and guide antioxidant
41A. Lezo et al. / Journal of Cystic Fibrosis 12 (2013) 35–41supplementation on an individual basis. Obtaining higher plasma
levels of vitamin C seems useful and feasible. Even so, the
optimal levels of fat soluble vitamins should be defined through
further studies. Patients with pancreatic insufficiency need a
careful monitoring of their redox balance because they are at risk
of excessive oxidative stress.
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